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Abstract Background Angiotensin converting enzyme
inhibitors (ACEIs) are among the most frequently pre-
scribed groups of medications. ACEI-induced adverse drug
reactions (ADRs) are the main reason to discontinue or
switch ACEI treatment. ADRs information is not available
in prescription databases. Objective To identify a proxy for
ACEI-induced ADRs in prescription databases. Setting The
Rotterdam Study is an ongoing prospective cohort study
that started in 1990 in the Netherlands and has included
14,926 subjects aged 45 years or older. Methods All ACEI
starters from 2000 to 2011 were identified using prescrip-
tion data within the Rotterdam Study. Participants were
classified into 4 mutually exclusive groups: continuing,
discontinuing, switching to angiotensin receptor blockers
(ARBs), and switching to other antihypertensives. For
categorization, the maximum time-interval between two
prescription periods was set at 3 and 6 months. Subse-
quently, primary care physician files were searched and
clinical events were classified as definite ADRs, probable
ADRs, possible ADRs and definite non-ADRs. Finally the
accuracy of different prescription patterns as indicators of
ADRs was evaluated. Main outcome measure Positive
predictive values (PPVs), negative predictive values
(NPVs), sensitivity and specificity of the prescription pat-
terns of the 4 groups were calculated. Results Totally, 1132
ACEI starters were included. The PPV for a definite ADR
was 56.1 % for switchers to ARB, while the PPVs for
switchers to other antihypertensives, and discontinuation
were 39.5 and 19.5 %, respectively. After including prob-
able ADRs and possible ADRs, PPVs for switchers to ARB
increased to 68.3 and 90.5 %. A 6-month interval gave
slightly higher PPVs compared to a 3-month interval
(maximum 6.1 % higher). The differences in NPVs
between 3 and 6-months interval groups were approxi-
mately 1.0 %. Conclusions Switching ACEIs to ARBs is
the best marker for ACEI-induced ADRs in prescription
databases.
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Impacts on Practice
• Because adverse drug reactions (ADRs) are poorly
registered in health care databases, it is difficult to
conduct reliable studies of drug-induced ADRs within
those databases without suitable proxies.
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• In prescription databases, switching from Angiotensin
Converting Enzyme Inhibitors to Angiotensin Receptor
Blockers is the best indicator for the ACEI-induced
adverse drug reactions.
• Applying the validated definition as a marker to
investigate genetic and environmental risk factors
associated with the occurrence of ACEI-induced ADRs
can increase the efficiency of epidemiological and
pharmacovigilance studies of ADRs.
Introduction
Angiotensin converting enzyme inhibitors (ACEIs) are
commonly prescribed for a wide range of indications in
both cardiovascular and renal disease, including hyper-
tension, heart failure, myocardial infarction, renal failure
and diabetic nephropathy [1]. They are first choice in
cardiovascular protection in the group of renin angiotensin
aldosterone system (RAAS) inhibitors [2]. It has been
shown that ACEIs reduce the risk of all-cause mortality
and cardiovascular mortality in both patients with hyper-
tension or diabetes mellitus [3, 4].
ACEIs are one of the most frequently prescribed groups
of medications worldwide, in the US they were prescribed
more than 150 million times per year since 2006 [5]. In the
Netherlands there were around 9 million ACEI prescrip-
tions in 2013 [6]. Furthermore, ramipril was the first anti-
hypertensive medication in 2013 with more than 24 million
prescriptions dispensed in community pharmacies in the
United Kingdom [7]. Adverse drug reactions (ADRs) are
one of the main reasons for discontinuation of ACEIs.
19 % of ACEI starters discontinued therapy due to ADRs
in a retrospective cohort study of outpatients who were
prescribed an ACEI for the first time in a mixed ethnicity
US population with 18 months follow-up [8].
Cough is among the most prevalent ADRs to ACEIs
with a reported incidence ranging from 5 to 35 %. Cough
may occur months and even years after ACEI initiation
[9, 10]. More rarely, patients can develop potentially life-
threatening angioedema that occurs in an estimated
0.1–0.7 % of patients [11]. Population based studies
showed that a large proportion of patients (44.2 %) who
discontinued ACEIs switched to an alternative antihyper-
tensive drug within 90 days of discontinuation, indicating
that they still need treatment [12]; however reason for
discontinuation or switching was not clear in prescription
datasets [12, 13]. According to the medical guidelines,
ACEIs have to be replaced by Angiotensin Receptor
Blockers (ARBs) when ADRs occur [9].
Electronic healthcare and prescription databases have
been widely used in ACEIs epidemiologic studies and
many of them have been linked to other data including
genetic data or laboratory test data [14, 15]. A major dif-
ficulty with conducting studies of ADRs is the fact that
these are poorly registered in clinical practice, thus health
care databases are generally incomplete sources in this
respect [16, 17]. Identifying proxies for ADRs based on
prescription patterns in prescription databases can facilitate
detection of ADRs for pharmacovigilance studies particu-
larly when the dispensing data is linked to other data, like
hospital admission data. Such a proxy will also create the
opportunity for the large scale studies of biomarkers (such
as genetic markers) that might predict the risk of devel-
oping ACEI-induced ADRs. ACEI-induced cough can lead
to discontinuation of therapy and thereby to a higher risk of
cardiovascular events. Angioedema on the other hand is a
severe ADR, that might even be life threatening. Other
effective antihypertensive drugs are available for patients
at risk, and therefore predicting ACEI-induced ADRs is of
clinical importance.
Aim of the study
The objective of this studywas to test changes in prescription
pattern as an appropriate proxy indicator for detecting the
signal of potential ACEI-induced ADRs using data from the
Rotterdam Study which contains both detailed drug dis-
pensing data as well as primary care physician data.
Ethical approval
The Rotterdam Study has been approved by the medical
ethics committee according to the Wet Bevolkingsonder-
zoek: ERGO (Population Study Act: Rotterdam Study),
executed by theMinistry ofHealth,Welfare and Sports of the
Netherlands. All participants gave written informed consent
to participate in the study, and to obtain information by
retrieval of medical records, use of blood and DNA for
research purposes, and publication of results, separately.
Methods
Data source
The Rotterdam Study is an ongoing prospective cohort
study that started in 1990 in Ommoord, a suburb of Rot-
terdam, the Netherlands. This study has included 14,926
subjects aged 45 years or older. The overall participation
was 72.0 % (14,926 of 20,744 eligible invited people). The
age distribution and social class of the participants is rep-
resentative for the Dutch elderly society. The aims and
details of the Rotterdam study have been described in detail
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previously [15, 18]. In the Rotterdam Study, pharmacy
dispensing data are available from January 1st, 1991. These
records include details about drug names and contents,
anatomical therapeutic chemical (ATC)-codes of medica-
tions, dosage forms, dispensing dates, number of units
dispensed, and prescribed daily dose. Therefore, calculat-
ing the duration of drug therapy is possible by dividing the
total number of tablets per prescription by the prescribed
daily number, so the theoretical end date of prescriptions
were calculated accordingly. Additionally the electronic
primary care medical records were also available. The
electronic medical records contained the notes and diag-
noses of the treating primary care physician.
Study population
A cohort of patients who newly started ACEIs after January
1st, 2000was identified retrospectivelywithin theRotterdam
Study. The inclusion criteria were: having at least 6 months
of valid medication history before starting the ACEI and not
having any ACEI prescription within that period to ascertain
that they are realACEI starters. These patientswere followed
until the end of the study period which was January 1st 2011,
or the date a patient died or moved outside of the catchment
area (loss of follow-up), whichever came first. Patients
whose medical records from general practitioners (GP) were
not available were excluded from the study population.
Outcome measure
Outcomes were measured as below in both, prescription
dispensing data and primary care medical records:
A. Prescription dispensing data were identified for all
included patients, based on ATC codes including
ACEIs (C09A, C09B), ARBs (C09C, C09D), beta
blockers (C07), calcium channel blockers (C08),
diuretics (C03) and/or antihypertensives (C02). Sub-
sequently the cohort was divided with the following
definitions: (Fig. 1a).
1. Continuation of ACEIs: patients who started ACEIs
and continued until the end of the follow up. We
allowed a maximum period of 3 months between a
renewal of an ACEI dispensing date and the
theoretical end date of the previous prescription
because the maximum time duration for a prescrip-
tion to be dispensed in the Netherlands is 3 months.
This group was further subdivided into 3 categories
depending on their situation when the follow up is
ended (end of study, out of study, death). These
categories were analysed separately and concomi-
tantly. Furthermore ‘‘end of study’’ and ‘‘out of
study’’ groups were analysed together (total minus
death), to studywhether change in definitions would
lead to differences in results. These patients were
assumed not to have experienced ADR and they
were considered as test negative group.
2. Discontinuation of ACEIs: patients who did not
renew their ACEI prescription within maximum
3 months after the theoretical end date of the last
ACEI prescription. Depending on their prescrip-
tion data within 3 months after the end of ACEIs
they were considered as stop (no new antihyper-
tensive), switchers to either ARBs or another
antihypertensive drug. These patients were
assumed to have possibly experienced an ADR
and were considered the test positive groups. The
theoretical end date of last ACEI prescription
would be the switch date or stop date.
B. In the primary care medical records, for the switching
and discontinuation groups, two medical students
manually searched 6 month before and 3 months after
the switch or stop date to identify the reason for
discontinuation or switching of ACEIs. This was done
by looking for registered clinical events which might
be related to ACEI use. Finally these reports were
checked and confirmed by a pharmacist.
Information from medical records was categorized into
4 groups (Fig. 1b):
1. Definite ADR: ADR due to ACEI was clearly
mentioned in the physician’s records and/or the
health problem resolved after discontinuation,
thus, the reason for discontinuation was an ADR.
2. Definite non-ADR: it was clearly mentioned that a
physician decided to change or stop medication
due to other reasons than an ACEI-induced ADR.
3. Nothing mentioned: Medical records were avail-
able but there was no relevant clinical event
mentioned within the required evaluation period.
Occurrence of ADR is still possible in this group.
4. Health problem mentioned: in this category, a
clinical event was recorded but it was unclear
whether it was due to the use of ACEIs. This
category was divided into 2 subgroups according
to the characteristics and nature of the mentioned
clinical event (probable and non-probable ADR).
Data analyses
Positive predictive values (PPVs) which are the probability
of correctly classifying a patient as having experienced an
ACEI-induced ADR were calculated for the test positive
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groups separately, for these calculations we considered the
proportion of test positive cohort (patients discontinued or
switched ACEIs) that were identified as definite ADR
cases, at least probable ADR cases (definite and probable
ADR), and the at least possible ADR cases (definite,
probable and possible ADR). Furthermore, PPVs were
separately calculated as the proportion of definite ACEI-
induced cough cases within patients that discontinued
ACEI or switched to other antihypertensives, since this is
the most frequently occurring ADR to ACEIs.
In order to calculate sensitivity and specificity, for each
patient from the discontinuation or switch group (test
positive), a patient from the continuation group (test neg-
ative) was selected and medical records were searched
from the start date of an ACEI for the same duration of
ACEI use that a test positive patient used ACEI; this
approach was applied to harmonize the time course
between test positive and test negative groups. Sensitivity
and specificity were calculated considering definite ADRs
only as probable and possible ADRs were not applicable
within the continuation group because there was no switch
or stop date by definition. Sensitivity in this study was
calculated as the proportion of actual ADR cases which are
correctly identified as ADR cases and specificity was also
calculated as the proportion of non-ADR cases which are
correctly identified as non-ADR.
Negative predictive values (NPVs) which are the prob-
ability of correctly classifying a patient as not having
experienced an ACEI-induced ADR were calculated in test
negative group for the at least possible (only the definite
ADR cases were deducted from the total number of
patients that continued ACEI use), and for at least probable
cases (both the definite ADR cases and the probable ADR
cases were deducted from the total). Two sided 95 %
confidence intervals (CI) were calculated for PPVs, NPVs,
sensitivity and specificity (Fig. 1c).
Fig. 1 The outcome measurement in both prescription dispensing data and primary care medical records and a table for calculating of the values.
ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker, ADR adverse drug reaction
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The sensitivity analyses were also performed with a
6 months interval instead of 3 months for defining the
prescription patterns.
Results
General characteristics and prescription patterns
In total, 1414 ACEI starters were found in the Rotterdam
study within the study period; 282 patients (19.9 %) did not
have medical records available and finally 1132 patients
were included in this study (44.4 % male, mean age
63.7 years). The mean and median follow up time for the
included patients were 1602 and 1496 days respectively.
Table 1 shows the baseline characteristics and the duration
of ACEI use stratified by ACEI use categories. Data are
shown both for the 3 and 6 months-time interval between
the theoretical end of ACEI prescription and start of a new
prescription. For both 3 and 6 months-time intervals,
approximately half of the ACEI starters discontinued their
medication (55.5 and 48.5 %, respectively) and that the
average ACEI treatment duration for all patients was
2 months longer when a 6 months-time interval was
applied instead of a 3 months interval. Switchers to ARBs
had the shortest mean duration of ACEI use of almost
10 months of ACEI consumption for both the 3- and
6 months interval. When the time interval was changed
from 3 to 6 months in the prescription data in total 96
patients changed categories which is 8.5 % of the study
population and most of them (82 out of 96) were from the
switching or discontinuation group to the continuation
group.
Primary care medical records
Table 2 only shows the detailed categorization of the study
population considering the 6 months interval because there
were only minor differences between 3 and 6 months
interval results. Within the group of definite ADRs, cough
and dizziness were the two most prevalent ADRs (73.5 and
4.5 % respectively). Angioedema occurred in 3.0 % of the
definite ADRs, and is shown separately as the most dan-
gerous ADR. Details of definite ADRs and probable ADRs
are presented in the annotation of Table 2.
Test positive groups
The highest PPVs were found for the switchers to ARBs in
all categories [definite ADR 56.1 % (95 % CI
48.8–63.1 %), at least probable ADR 68.9 % (95 % CI
62.0–75.1 %) and at least possible ADR 90.9 % (95 % CI
85.9–94.2 %)]. The PPV for definite ADR was 56.1 %
(95 % CI 48.8–63.1 %) when the 6 months-time interval
Table 1 General characteristics of included patients in the study
Number
(% of total)
Mean age
(years) [SD]
Gender
(% male)
Median ACEI
treatment duration
(days)
Mean ACEI treatment
duration (days) [SD]
3 Months interval
Continuation (N = 503) (44.5 %)
End of study 267 (23.5) 62 [6.7] 50.2 1219 1340 [1035]
Out of study 135 (12) 62.9 [6.2] 49.6 1350 1451 [1046]
Death 101 (9) 68.8 [7.3] 51.5 508 756 [706]
Stop 308 (27) 64.5 [7] 40.6 207.5 477 [628]
Switch to other antihypertensive than ARB 134 (12) 63.9 [6.5] 45.5 116.5 419 [656]
Switch to ARB 187 (16.5) 62.7 [5.9] 34.2 115 296 [464]
Total 1132 (100) 63.7 [6.9] 44.4 343 785 [909]
6 Months interval
Continuation (N = 585) (51.5 %)
End of study 299 (26.5) 62 [6.8] 50.5 1207 1347 [1049]
Out of study 167 (14.5) 62.9 [6.1] 48.5 1410 1533 [1047]
Death 119 (10.5) 69 [7.2] 51.3 564 736 [673]
Stop 261 (23 %) 64.3 [6.9] 40.2 179 466 [643]
Switch to other antihypertensive than ARB 106 (9.5) 64 [6.3] 40.6 102.5 343 [532]
Switch to ARB 180 (16) 62.8 [5.7] 34.4 115 293 [473]
Total 1132 (100) 63.7 [6.9] 44.4 397 845 [948]
ARB Angiotensin receptor blocker, SD standard deviation
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was taken into account which was slightly higher than
55.0 % (95 % CI 47.9–62.0 %) for the 3 months-time
interval. Except for the category of at least possible, for all
other categories these higher values for the 6 months
interval were observed. Cough is the most prevalent ADR
of ACEIs, so PPVs for the definite ACEI-induced cough
cases were calculated separately. The highest value was
46.1 % (95 % CI 38.9–53.4 %) for the switchers to ARBs
considering the 6 months-time interval, in all groups which
were considered as test positive, the 6 months interval
showed higher PPVs for ACEI-induced cough, (Table 3).
Sensitivity was 91.8 % (95 % CI 85.1–95.9 %) and
specificity was 68.4 % (95 % CI 62.4–73.8 %) in switchers
to ARBs when 6 months interval was applied and both
were higher compared with the 3 months gap in the defi-
nition (Table 3).
Test negative groups
The differences in NPVs for both at least probable and at
least possible between 3 and 6 months interval group were
very small (approximately 1 %) and inconsistent. Within
the groups, the differences between the highest and lowest
NPVs for subgroups of ‘‘end of study’’, ‘‘out of study’’,
‘‘death’’, ‘‘total minus death’’ and ‘‘total continuation’’
were also small with a maximum of 2.4 % (Table 4).
Table 2 Number of ACEI starters in different categories both according to the prescription data and medical records
Total (N = 1132) Switchers to
ARB (N = 180)
(16 %)
Switchers to other
antihypertensive than
ARB (N = 106)
(9.5 %)
Stoppers
(N = 261)
(23 %)
Continuation (N = 585) (51.5 %)
Out of study
(N = 167)
(14.5 %)
Death
(N = 119)
(10.5 %)
End of study
(N = 299)
(26.5 %)
Definite ADR (N = 222) (19.5 %)
Cough (N = 163) 83 25 35 4 3 13
Angioedema (N = 7) 3 1 1 0 1 1
Othersa (N = 52) 15 16 15 3 1 2
Total 101 (56 %) 42 (39.5 %) 51 (19.5 %) 7 5 16
28 (5 %)
Definite Non-ADR (N = 48) (4.3 %)
No need (N = 11) 0 1 10 N/A N/A N/A
Not effective (N = 15) 4 4 7 N/A N/A N/A
Othersb (N = 22) 6 5 11 N/A N/A N/A
Total 10 (5.5 %) 10 (9.5 %) 28 (11 %) N/A
Nothing mentioned (N = 628) (55.5 %) 40 (22.5 %) 25 (23.5 %) 132 (50.5 %) 124 89 218
431 (73.5 %)
Health problem mentioned (N = 234) (20.7 %)
Probable ADRc (N = 197) 22 20 43 35 21 56
Non-probable ADRd (N = 37) 7 9 7 1 4 9
Total 29 (16 %) 29 (27.5 %) 50 (19 %) 36 25 65
126 (21.5 %)
The interval between a renewal of an ACEI prescription and the theoretical end date of the previous prescription was 6 months. ACEI
Angiotensin converting enzyme inhibitor, ARB Angiotensin receptor blocker, N/A Not applicable
a Allergic reaction (N = 1), Renal dysfunction (N = 2), Runny nose (N = 2), Sexual dysfunction (N = 1), Tiredness (N = 6), Not mentioned
(N = 9), Chest pain (N = 1) Decreased taste (N = 1), Dizziness (N = 9), Dizziness plus (N = 1), Gastrointestinal (N = 4), Headache (N = 2),
Hiccups (N = 1), Hyperkalemia (N = 2), Itching (N = 3), Itching rash (N = 5), Muscular crumps (N = 1), Nausea (N = 1)
b Angioedema history (N = 1), Bad taste (N = 1), Cerebrovascular event (N = 1), Do not like (N = 1), Drug interaction (N = 2), Disease
interaction (N = 3), Hypotension (N = 2), Self-stop (N = 3), Surgery (N = 1), Not mentioned (N = 5), Short change (N = 2)
c Allergic reaction (N = 1), Angioedema (N = 2), Cough (N = 48), Cough plus (N = 11), Asthma (N = 4), Bronchitis (N = 26), Common
cold (N = 6), COPD (N = 8), Dry cough (N = 7), Flu (N = 1), Infectious cough (N = 28), Pneumonia (N = 7), Cough with sputum (N = 4),
Dizziness (N = 16), Dizziness plus (N = 1), Dyspnea (N = 5), Hypersensitivity (N = 1), Itching (N = 2), Itching rash (N = 3), Itching throat
(N = 2), Rash (N = 3), Tiredness plus (N = 1), Tiredness (N = 3), Sexual dysfunction (N = 2), Shortness breath (N = 5)
d Anxiety (N = 1), Bad feeling (N = 6), Body pain (N = 1), Edema (N = 1), Gastrointestinal (N = 5), Hair loss (N = 1), Hospitalization
(N = 1), Hand hypoxia (N = 1), Increased blood urea (N = 1), Muscular crumps (N = 5), Muscular pain (N = 1), Nausea (N = 2), Not
tolerate (N = 4), Renal dysfunction (N = 3), Runny nose (N = 1), Swollen feet (N = 1), Not mentioned (N = 1) Pulmonary embolism (N = 1)
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Discussion
Based on PPV, NPV, sensitivity and specificity, this study
showed that switching from an ACEI to an ARB allowing
6 months-time interval between last use of ACEI and start
of ARB, is the best marker in the prescription database of
the Rotterdam Study for ACEI-induced ADRs. This finding
offers the possibility to use prescription databases to
identify patients who have experienced ACEI-induced
ADRs even in the absence of clinical data or specific ADR
registrations. This was also demonstrated for ACEI-in-
duced cough specifically, because switchers from ACEIs to
ARBs had the highest PPVs among all groups of ACEI
prescription patterns for either definite, probable or possi-
ble ADRs and also for the definite ACEI-induced cough
cases only. A 6 months interval gave slightly higher PPV
compared with a 3 months interval, and both sensitivity
and specificity were higher using a 6 months interval.
In all studies that compared discontinuation between
different classes of antihypertensive drugs ARBs were used
without switching or discontinuation for the longest period
followed by ACEI, while the time intervals for defining
discontinuation or switch in prescription data were not
consistent in all of them [12, 19, 20]. In this study, 3 and
6 months-time intervals were used to find the best interval
in terms of indicating ADRs and accuracy to include real
stoppers, switchers and continuers because previous studies
have shown that time-interval influence the categorization
in hypertensive therapy [21]. Out of the total 96 patients
who changed categories when the interval changed from 3
to 6 months, 82 changes (85.5 %) were from groups of
switching and discontinuation to the continuation group,
which suggests that using the 6 month interval is probably
better to prevent misclassification because patients who
restart are not expected to have stopped due to an ADR
previously. Morimoto et al. investigated ACEI-induced
ADRs and found that 32.4 % of ACEI starters discontinued
ACEI, of whom 19 % discontinued use, due to ADRs after
a maximum of 18 months follow up [8]. In our study,
48.5 % of the ACEI starters discontinued their ACEI when
the 6 months-time interval was used and ACEIs were on
average used for about 28 months in the whole study
population when considering a maximum interval of
6 months within the prescriptions.
Other examples where prescription data were validated
as a marker for clinical events have been published. For
instance, in the Rotterdam Study, using repeated nitrate
prescription has been shown to be a suitable marker for
angina pectoris in electronic healthcare databases [22] and
also changes in prescription data were used previously as
Table 3 Positive predictive values for the total adverse drug reactions and cough only cases within the test positive groups (patients who
discontinued or switched), Sensitivity and specificity considering the definite adverse drug reactions
Switchers to ARB Switchers to other
than ARB
Stoppers Switchers total Total discontinuation
PPV definite % (95 % CI)
3 M 55.0 (47.9–62.0) 33.5 (26.1–41.9) 17.5 (13.6–22.1) 46.1 (40.7–51.5) 32.1 (28.5–35.8)
6 M 56.1 (48.8–63.1) 39.6 (30.8–49.1) 19.5 (15.1–24.7) 50.0 (44.2–55.7) 35.4 (31.5–39.5)
PPV at least probable % (95 % CI)
3 M 68.9 (62.0–75.1) 52.2 (43.8–60.5) 35.7 (30.5–41.2) 61.9 (56.5–67.1) 49.1 (45.2–53.0)
6 M 68.3 (61.2–74.6) 58.4 (48.9–67.4) 36.0 (30.4–42.0) 64.6 (58.9–70.0) 51.0 (46.8–55.1)
PPV at least Possible % (95 % CI)
3 M 90.9 (85.9–94.2) 83.5 (76.3–88.9) 87.6 (83.5–90.8) 87.8 (83.8–90.9) 87.7 (84.9–90.0)
6 M 90.5 (85.4–94.0) 82.0 (73.7–88.2) 86.5 (81.9–90.2) 87.4 (83.0–90.7) 87.0 (83.9–89.5)
PPV definite Cough cases only % (95 % CI)
3 M 45.4 (38.4–52.6) 19.4 (13.6–26.9) 11.6 (8.5–15.7) 34.5 (29.5–39.9) 23.3 (20.2–26.8)
6 M 46.1 (38.9–53.4) 23.5 (16.5–32.5) 13.4 (9.8–18.0) 37.7 (32.3–43.5) 26.1 (22.6–29.9)
Sensitivitya definite cases % (95 % CI)
3 M 91.1 (84.4–95.1) 95.7 (85.7–98.8) 80.6 (69.5–88.3) 92.5 (87.3–95.6) N/A
6 M 91.8 (85.1–95.9) 93.3 (82.1–97.7) 80.9 (69.5–88.7) 92.2 (86.9–95.5) N/A
Specificitya definite cases % (95 % CI)
3 M 67.8 (61.9–73.1) 59.7 (53.1–65.9) 53.7 (49.5–57.8) 64.1 (59.7–68.2) N/A
6 M 68.4 (62.4–73.8) 61.6 (54.1–68.7) 54.2 (49.6–58.7) 65.7 (61.0–70.1) N/A
PPV positive predictive value, ARB angiotensin receptor blocker, CI confidence interval, N/A not applicable
a To calculate the sensitivity and specificity, where it was possible, for each patient from the test positive groups (discontinuation or switch), a
patient from the test negative group (continuation) was selected and medical records were searched for the same duration of ACEI use
3 M and 6 M denote time intervals in months between a renewal of an ACEI prescription and the theoretical end date of the previous prescription
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an indicator of ADR due to statins [23]. In a sample of 63
cases that switched, discontinued or reduced the dose of
their statin therapy, 68 % suffered from ADRs induced by
statins and this proxy was used within prescription data for
genetic association studies where large numbers of cases
are needed [24]. This study tried to identify the reason for
discontinuation and switching in general practitioners (GP)
files to find the best marker in prescription data for ACEI-
induced ADRs, and specifically cough. This study was
conducted in the Rotterdam Study, which is a large cohort
study within the Netherlands with a good generalizability
to the Caucasian population of 45 years and older [25], so
the results can be translated to other similar databases.
Pharmacies in the Netherlands are allowed to deliver
medication for a maximum of 90 days; therefore the reg-
ular time interval for refilling a prescription is 3 months.
Results of this study should be used with caution in
countries with different intervals for prescription refill.
Additionally the proxy cannot differentiate between the
different ACEI-induced ADRs, however for cough as the
most prevalent ADR, results showed a high predictive
value for definite cases [46.1 % (95 % CI 38.9–53.4 %)].
Because usually ADRs are not well registered, the use of
electronic healthcare databases can increase the number of
cases of ADRs that can be found, and can decrease the
amount of time and costs spent in searching for these cases
in epidemiologic studies. Many prescription databases can
be linked to other types of data, including but not limited to
hospital data, genetic data, socio-demographic data and
laboratories-test data [26].
Hospital data have been used previously to detect and
report ADRs for pharmacovigilance studies [27]. If linkage
to hospital data is possible, this can strengthen the validity
for the detection of ACEI related ADRs, especially those
ADRs that need hospital admission like angioedema.
However, for ADRs that do not require hospitalization (like
cough) the use of drug dispensing databases might be a
good alternative for pharmacovigilance studies.
An important limitation of our study is that only the
diagnoses of general practitioners (GP) records were con-
sidered. It was not possible to check specialist records or to
interview patients. This might have led to misclassification
because some clinical events might have been missed,
misdiagnosed or not been registered in GP records [28].
The number of general practitioners visited by the patients
in the Rotterdam Study is limited to the specific region and
that is a single centre study, so the variation in physician’s
attitude to diagnose the ACEI-induced ADRs might be less
comparing to multicentre studies, however it cannot be
ruled out.
Conclusion
In conclusion, switching from ACEIs to ARBs is the best
marker in prescription databases and might be useful to
investigate genetic and environmental risk factors associ-
ated with the occurrence of ACEI-induced ADRs. Using
such data might increase the efficiency of epidemiological
studies of ADRs, especially of the ones which are not
coded and found back in health care databases.
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